Furthermore, to assess the prognostic roles of the combined expression of TRIB2 and MAP3K1 in glioma, we obtained the following four combinations using 91 tumor samples according to the IHC expression levels: TRIB2High/MAP3K1High, TRIB2High/MAP3K1Low, TRIB2Low/MAP3K1High, and TRIB2Low/MAP3K1Low. The gene discussed is MAP3K1; the disease is central nervous system cancer.